[go: up one dir, main page]

DE3160084D1 - Novel erythromycin compounds - Google Patents

Novel erythromycin compounds

Info

Publication number
DE3160084D1
DE3160084D1 DE8181302328T DE3160084T DE3160084D1 DE 3160084 D1 DE3160084 D1 DE 3160084D1 DE 8181302328 T DE8181302328 T DE 8181302328T DE 3160084 T DE3160084 T DE 3160084T DE 3160084 D1 DE3160084 D1 DE 3160084D1
Authority
DE
Germany
Prior art keywords
novel erythromycin
erythromycin compounds
compounds
novel
erythromycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE8181302328T
Other languages
English (en)
Inventor
Yoshiaki Watanabe
Shigeo Morimoto
Sadafumi Omura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26416408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3160084(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from JP7525880A external-priority patent/JPS572298A/ja
Priority claimed from JP55159128A external-priority patent/JPS5782400A/ja
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE3160084D1 publication Critical patent/DE3160084D1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE8181302328T 1980-06-04 1981-05-27 Novel erythromycin compounds Expired DE3160084D1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP7525880A JPS572298A (en) 1980-06-04 1980-06-04 Erythromycin derivative
JP55159128A JPS5782400A (en) 1980-11-12 1980-11-12 Erythromycin derivative

Publications (1)

Publication Number Publication Date
DE3160084D1 true DE3160084D1 (en) 1983-03-31

Family

ID=26416408

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8181302328T Expired DE3160084D1 (en) 1980-06-04 1981-05-27 Novel erythromycin compounds

Country Status (4)

Country Link
US (1) US4331803A (de)
EP (1) EP0041355B1 (de)
DE (1) DE3160084D1 (de)
NL (1) NL930083I2 (de)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5896097A (ja) * 1981-12-01 1983-06-07 Taisho Pharmaceut Co Ltd エリスロマイシンｂ誘導体
JPS5896098A (ja) * 1981-12-03 1983-06-07 Taisho Pharmaceut Co Ltd エリスロマイシンａ誘導体
JPS60120895A (ja) * 1983-12-02 1985-06-28 Taisho Pharmaceut Co Ltd ６−０−メチル−２′−０，ν−ビス（ベンジルオキシカルボニル）−ν−デメチルエリスロマイシンａの製法
JPS60214796A (ja) * 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
IL75908A0 (en) * 1984-08-31 1985-12-31 Abbott Lab Macrolide alkylation process
JPS61103890A (ja) * 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシンａ誘導体
GB8506380D0 (en) * 1985-03-12 1985-04-11 Beecham Group Plc Chemical compounds
HUT42502A (en) 1985-03-12 1987-07-28 Beecham Group Plc Process for preparing new erythromycine derivatives
US4670549A (en) * 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
JPS61229895A (ja) * 1985-04-03 1986-10-14 Nippon Zeon Co Ltd 保護化デス−ｎ−メチルエリスロマイシン誘導体
US5175150A (en) * 1985-08-31 1992-12-29 Kitasato, Kenkyusho Erythromycin derivative
US4672056A (en) * 1985-11-12 1987-06-09 Abbott Laboratories Erythromycin A derivatives and method of use
US4640910A (en) * 1985-11-12 1987-02-03 Abbott Laboratories Erythromycin A silylated compounds and method of use
US5149639A (en) * 1986-03-24 1992-09-22 Abbott Laboratories Biologically pure cultures of streptomyces and use thereof in macrolide antibiotic production
US4874748A (en) * 1986-03-24 1989-10-17 Abbott Laboratories Cloning vectors for streptomyces and use thereof in macrolide antibiotic production
JPS63107994A (ja) * 1986-05-02 1988-05-12 Taisho Pharmaceut Co Ltd エリスロマイシン誘導体
JPH0633312B2 (ja) * 1986-05-02 1994-05-02 大正製薬株式会社 １４−ハイドロキシエリスロマイシン誘導体およびその製造方法
US4740502A (en) * 1986-06-20 1988-04-26 Abbott Laboratories Semisynthetic erythromycin antibiotics
EP0260938B1 (de) 1986-09-18 1992-12-09 Taisho Pharmaceutical Co. Ltd Erythromycin-A-Derivate und Verfahren zu ihrer Herstellung
US5302705A (en) * 1989-10-07 1994-04-12 Taisho Pharmaceutical Co., Ltd. 6-O-methylerythromycin a oxime derivatives
US5141926A (en) * 1990-04-18 1992-08-25 Abbott Laboratories Erythromycin derivatives
HRP930014A2 (en) * 1993-01-08 1994-08-31 Pliva Pharm & Chem Works 9-deoxo-9a-aza-11-deoxy-9a-homoeritromycin a 9a, 11-cyclic carbamates
CA2189001A1 (en) * 1994-04-26 1995-11-02 Nobuhiro Narita Medicinal composition as a remedy for nonsmall cell lung cancer
US5498424A (en) * 1994-11-30 1996-03-12 Klein; Ira Method of treating obesity
US5747466A (en) * 1995-11-08 1998-05-05 Abbott Laboratories 3-deoxy-3-descladinose derivatives of erythromycins A and B
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5756473A (en) * 1995-11-21 1998-05-26 Abbott Laboratories 6-O-methyl erythromycin D and process for making
US5858986A (en) 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
US5844105A (en) * 1996-07-29 1998-12-01 Abbott Laboratories Preparation of crystal form II of clarithromycin
DE97934319T1 (de) 1996-07-29 2004-08-26 Abbott Laboratories, Abbott Park Herstellung von kristallinen form ii von clarithromycin
US5804565A (en) * 1996-09-24 1998-09-08 Taisho Pharmaceutical Co., Ltd. Erythromycin A derivatives
WO1998023628A1 (fr) 1996-11-27 1998-06-04 Taisho Pharmaceutical Co., Ltd. Derives de l'erythromicine a
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
US5864023A (en) * 1997-02-13 1999-01-26 Abbott Laboratories 3'-N'oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives
US6165986A (en) * 1997-03-10 2000-12-26 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
US6140479A (en) * 1997-03-24 2000-10-31 Taisho Pharmaceuticals Co., Ltd. Erythromycin a derivatives
US5929219A (en) * 1997-09-10 1999-07-27 Abbott Laboratories 9-hydrazone and 9-azine erythromycin derivatives and a process of making the same
US6174865B1 (en) 1997-09-25 2001-01-16 Ira Klein Method of treating hypertriglyceridemia with an erythromycin compound
US5780604A (en) * 1997-09-26 1998-07-14 Abbott Laboratories 11,12-cyclic phosphite or phosphate derivatives of erythromycin and related macrolides
WO1999021868A1 (fr) 1997-10-29 1999-05-06 Taisho Pharmaceutical Co., Ltd. Derives d'erythromycine a
US5852180A (en) * 1997-11-17 1998-12-22 Abbott Laboratories Chemical synthesis of 6-O-alkyl erythromycin A
IL135792A0 (en) * 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
US5892008A (en) * 1997-12-16 1999-04-06 Abbott Laboratories Process for the preparation of 6-O-methyl erythromycin a using 9-hydroxy erythromycin derivatives
AP1060A (en) * 1998-01-02 2002-04-23 Pfizer Prod Inc Novel erythromycin derivatives.
HRP980189B1 (en) * 1998-04-06 2004-04-30 Pliva Pharm & Chem Works Novel 15-membered lactams ketolides
SI20150A (sl) * 1999-02-19 2000-08-31 Lek, Tovarna Farmacevtskih In Direktno stisljivi matriks za nadzorovano sproščanje celodnevne doze klaritromicina
CN1351608A (zh) * 1999-05-24 2002-05-29 辉瑞产品公司 13－甲基红霉素衍生物
US6420535B1 (en) 1999-06-07 2002-07-16 Abbott Laboratories 6-O-carbamate ketolide derivatives
US6417366B2 (en) 1999-06-24 2002-07-09 Abbott Laboratories Preparation of quinoline-substituted carbonate and carbamate derivatives
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
GB9915745D0 (en) * 1999-07-06 1999-09-08 Biochemie Sa Organic compounds
US6569836B2 (en) 1999-12-02 2003-05-27 Abbott Laboratories 6-O-alkyl-2-nor-2-substituted ketolide derivatives
US6627743B1 (en) 1999-12-03 2003-09-30 Abbott Laboratories 6-O-methylerythromycin A crystal form III
SK8322002A3 (en) * 1999-12-16 2003-02-04 Teva Pharma Processes for preparing clarithromycin polymorphs and novel polymorph IV
RU2002118308A (ru) * 2000-01-11 2004-02-20 Тева Фамэситикл Индастрис Лтд. (Il) Способы получения полиморфных модификаций кларитромицина
US6946446B2 (en) 2000-02-24 2005-09-20 Abbott Laboratories Anti-infective agents useful against multidrug-resistant strains of bacteria
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
HRP20020709A2 (en) * 2000-02-29 2004-12-31 Teva Pharma Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
US6605707B1 (en) 2000-03-23 2003-08-12 Abbott Laboratories Process for the preparation of 6-O-propargyl erythromycin derivatives
DE60138876D1 (de) * 2000-03-28 2009-07-16 Sandoz Ag Geschmackmaskierte granulierte teilchen
TR200401093T4 (tr) 2000-05-15 2004-11-22 Ranbaxy Laboratories, Ltd. Eritromisin türevlerinin selektif metilasyonu için maliyet etkin bir metot
CA2419873A1 (en) 2000-08-23 2002-02-28 Wockhardt Limited Process for preparation of anhydrous azithromycin
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6455680B1 (en) 2000-12-21 2002-09-24 Abbott Laboratories Methods utilizing aryl thioimines in synthesis of erythromycin derivatives
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
TWI246515B (en) 2001-05-30 2006-01-01 Abbott Lab An arylation method for the functionalization of O-allyl erythromycin derivatives
BR0212259A (pt) * 2001-08-29 2004-10-19 Ranbaxy Lab Ltd Formulação de liberação controlada de claritromicina ou tinidazol
US20030091627A1 (en) * 2001-10-31 2003-05-15 Vinay Sharma Rate-controlled delivery of macrolides
AU2003211923A1 (en) * 2002-02-13 2003-09-04 Taisho Pharmaceutical Co., Ltd. Process for producing erythromycin a derivative
EP1490090A4 (de) 2002-02-22 2006-09-20 New River Pharmaceuticals Inc Wirkstoff-abgabesystem und verfahren zum schutz und zur verabreichung von wirkstoffen
AU2003214506A1 (en) * 2002-04-03 2003-10-13 Ranbaxy Laboratories Limited Clarithromycin formulations having improved bioavailability
US6843854B2 (en) 2002-05-31 2005-01-18 Purdue Research Foundation Method and apparatus for separating a component from a mixture
WO2004080391A2 (en) * 2003-03-10 2004-09-23 Optimer Pharmaceuticals, Inc. Novel antibacterial agents
US7435805B2 (en) 2003-05-30 2008-10-14 Glaxpsmithkline Istrazivacki O-alkyl macrolide and azalide derivatives and regioselective process for their preparation
CA2530581A1 (en) * 2003-06-23 2005-01-06 Auspex Pharmaceuticals Novel therapeautic agents for the treatment of cancer, metabolic diseases and skin disorders
CA2533358C (en) 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US8313775B2 (en) 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
JP2006528189A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質産物、その使用法および製剤
JP2007502296A (ja) 2003-08-11 2007-02-08 アドバンシス ファーマスーティカル コーポレイション ロバストペレット
WO2005016278A2 (en) 2003-08-12 2005-02-24 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
EP1658034A4 (de) 2003-08-29 2011-06-22 Middlebrook Pharmaceuticals Inc Antibiotisches produkt, seine verwendung und formulierung
US8460710B2 (en) 2003-09-15 2013-06-11 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2003263482A1 (en) * 2003-09-25 2005-04-14 Ranbaxy Laboratories Limited 3'-n-substituted-3-o-substituted erythronolide a derivatives
CA2572292A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US20060111560A1 (en) * 2004-11-01 2006-05-25 Glenmark Pharmaceuticals Limited Process for the preparation of crystalline form II of clarithromycin
HRP20100253T1 (hr) 2004-12-21 2010-06-30 Pfizer Products Inc. Makrolidi
US7582611B2 (en) 2005-05-24 2009-09-01 Pfizer Inc. Motilide compounds
US20060293261A1 (en) * 2005-06-24 2006-12-28 Taisho Pharmaceutical Co., Ltd. Clarithromycin or a salt thereof for the treatment or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli
US20070015719A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International Limited Nanoparticulate clarithromycin formulations
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
EP2023721A2 (de) * 2006-06-05 2009-02-18 Auspex Pharmaceuticals Inc. Herstellung und verwendung substituierter erythromycin-analoge
JP2010501541A (ja) 2006-08-24 2010-01-21 ウォックハート リサーチ センター 抗菌活性を有する新規マクロライド及びケトライド
US20090054634A1 (en) * 2007-08-09 2009-02-26 Vinod Kumar Kansal Process for the preparation of clarithromycin
US20090069255A1 (en) * 2007-09-11 2009-03-12 Protia, Llc Deuterium-enriched clarithromycin
US9453042B2 (en) * 2007-10-25 2016-09-27 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
CN102245195B (zh) 2008-10-24 2016-01-13 森普拉制药公司 使用含三唑的大环内酯的生物防御
CN101875678B (zh) * 2009-04-30 2012-06-27 浙江华义医药有限公司 一种制备克拉霉素的方法
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
CN102724874B (zh) 2009-09-10 2018-06-01 森普拉制药公司 治疗疟疾、结核病和mac疾病的方法
PL2550286T3 (pl) 2010-03-22 2016-07-29 Cempra Pharmaceuticals Inc Krystaliczne postaci makrolidu i ich zastosowanie
CN102250173B (zh) * 2010-05-18 2015-07-08 上海医药工业研究院 一种6-o-甲基红霉素a衍生物和克拉霉素的制备方法
CN102250180B (zh) * 2010-05-18 2015-07-22 上海医药工业研究院 2’,4”-o-二(三甲基硅基)-红霉素a衍生物和克拉霉素制备方法
CA2799937A1 (en) 2010-05-20 2011-11-24 Cempra Pharmaceuticals, Inc. Processes for preparing macrolides and ketolides and intermediates therefor
JP6042334B2 (ja) 2010-09-10 2016-12-14 センプラ ファーマシューティカルズ，インコーポレイテッド 疾患治療のための水素結合形成フルオロケトライド
KR101657751B1 (ko) 2010-12-09 2016-09-19 욱크하르트 리미티드 케토라이드 화합물
WO2012117357A2 (en) 2011-03-01 2012-09-07 Wockhardt Limited Process for preparation of ketolide intermediates
CN103619863B (zh) 2011-03-22 2016-03-16 沃克哈特有限公司 酮内酯化合物的制备方法
SG11201405895UA (en) 2012-03-27 2014-10-30 Cempra Pharmaceuticals Inc Parenteral formulations for administering macrolide antibiotics
EP2671571A1 (de) 2012-06-05 2013-12-11 Sanovel Ilac Sanayi ve Ticaret A.S. Formulierungen von Clarithromycin mit gesteuerter Freisetzung
MD20150056A2 (ro) 2012-12-24 2015-09-30 Ramot At Tel-Aviv University Ltd Agenţi pentru tratarea bolilor genetice cauzate de mutaţii nonsens şi metode de identificare a acestora
RU2015138796A (ru) 2013-03-14 2017-04-19 Семпра Фармасьютикалс, Инк. Способы и составы для лечения респираторных заболеваний
HK1218864A1 (zh) 2013-03-15 2017-03-17 森普拉制药公司 用於制备大环内酯抗菌剂的收敛方法
CN105801642B (zh) * 2016-03-11 2019-03-26 北京理工大学 一种制备6,11-双-o-甲基红霉素a的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2653899A (en) * 1952-04-14 1953-09-29 Lilly Co Eli Erythromycin, its salts, and method of preparation
US3674773A (en) * 1970-10-06 1972-07-04 Abbott Lab Erythromycin derivatives
US3923784A (en) * 1973-09-10 1975-12-02 Hoffmann La Roche Erythromycin a derivatives

Also Published As

Publication number Publication date
EP0041355A1 (de) 1981-12-09
EP0041355B1 (de) 1983-02-23
NL930083I1 (nl) 1993-09-16
NL930083I2 (nl) 1994-12-01
US4331803A (en) 1982-05-25

Similar Documents

Publication Publication Date Title
DE3160084D1 (en) Novel erythromycin compounds
GB2081717B (en) Hereocyclic compounds
SG69286G (en) 4-chlorothiazolyl-containing compounds
JPS5767568A (en) Benzisoselenazolone compound
JPS57120588A (en) Nortropanol compound
DE3171475D1 (en) Aryl-phenyl-acetylene compounds
JPS57120575A (en) Imidazolylphenylamidine compound
PT75620A (en) Novel compounds
JPS5724328A (en) Dienylmethacrylate compound
JPS5758696A (en) Macrolide compound
PT74377B (en) Novel compounds
GB2083046B (en) Bestatin-related compounds
PT72752B (en) Compounds
JPS5749666A (en) Helichromic compound
GB2067992B (en) Malonamidooxadethiacephem compounds
DE3162041D1 (en) Hydrouracil compounds
JPS5795972A (en) 2-guanidino-4-heteroarylthiazole compound
JPS56125389A (en) Spiro-dihydrobenzofuran compound
JPS5794051A (en) Halotriazinyl-containing compound
GB2082577B (en) Polyazaheterocyclic compounds
ZA812675B (en) Mycotoxin-binding compound
DE3160271D1 (en) Monoalkyl-fluorotin compounds
ZA814789B (en) Macrolide antibioties
JPS5785396A (en) 4-carbamoyloxy-oxazaphosphorine compound
ZA825525B (en) Novel compounds

Legal Events

Date Code Title Description
V448 Application of spc

Free format text: PRODUCT NAME: CLARITHROMYCIN; REGISTRATION NO/DATE: 19219.00.00, 19901031

Spc suppl protection certif: 193 75 096

Filing date: 19930701

Free format text: PRODUCT NAME: CLARITHROMYCIN + KALIUMSORBAT; REGISTRATION NO/DATE: 19219.00.01, 19911031

Spc suppl protection certif: 193 75 098

Filing date: 19930701

V457 Spc granted

Free format text: PRODUCT NAME: CLARITHROMYCIN; REGISTRATION NO/DATE: 19219.00.00, 19901031

Spc suppl protection certif: 193 75 096

Filing date: 19930701

V472 Application for supplementary protection certificate rejected

Free format text: PRODUCT NAME: CLARITHROMYCIN + KALIUMSORBAT; REGISTRATION NO/DATE: 19219.00.01, 19911031

Spc suppl protection certif: 193 75 098

Filing date: 19930701

V507 Internal change in the state of proceedings of spc, spc applied

Free format text: PRODUCT NAME: CLARITHROMYCIN + KALIUMSORBAT; REGISTRATION NO/DATE: 19219.00.01, 19911031

Spc suppl protection certif: 193 75 098

Filing date: 19930701

V472 Application for supplementary protection certificate rejected

Free format text: PRODUCT NAME: CLARITHROMYCIN + KALIUMSORBAT; REGISTRATION NO/DATE: 19219.00.01, 19911031

Spc suppl protection certif: 193 75 098

Filing date: 19930701

V464 Spc expired

Free format text: PRODUCT NAME: CLARITHROMYCIN; REGISTRATION NO/DATE: 19219.00.00, 19901031

Spc suppl protection certif: 193 75 096

Filing date: 19930701